Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.

[1]  M. Inbar,et al.  Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. , 2007, Gynecologic oncology.

[2]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[3]  J. McAlpine,et al.  Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. , 2005, Gynecologic oncology.

[4]  M. Inbar,et al.  Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. , 2004, Gynecologic oncology.

[5]  R. Coleman,et al.  Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. , 2004, Gynecologic oncology.

[6]  E. Eisenhauer,et al.  Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG , 2004 .

[7]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.

[8]  C. Dunton.  Management of treatment-related toxicity in advanced ovarian cancer. , 2002, The oncologist.

[9]  D. Armstrong.  Relapsed ovarian cancer: challenges and management strategies for a chronic disease. , 2002, The oncologist.

[10]  A. Munkarah,et al.  Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. , 2002, The oncologist.

[11]  E. Rowinsky.  Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule? , 2002, The oncologist.

[12]  P. Rose,et al.  Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. , 2001, Gynecologic oncology.

[13]  H. Homesley,et al.  A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. , 2001, Gynecologic oncology.

[14]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Dunton,et al.  Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Lissoni,et al.  Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Eisenhauer,et al.  Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A Gordon,et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Gore,et al.  Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Edmund E. Kim,et al.  Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Elisa T. Lee,et al.  Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.

[22]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[23]  George Casella,et al.  Refining binomial confidence intervals , 1986 .

[24]  G. Ross,et al.  Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  E. Eisenhauer,et al.  Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.